TGFbeta in cancer and other disease - AACR special conference in cancer research.
Jachimczak
Piotr
P
Antisense Pharma GmbH, Josef-Engert-Strasse 9, D-93053 Regensburg, Germany. jachimczak@t-online.de
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D053781:Transforming Growth Factor beta2
D000911:Antibodies, Monoclonal; D001549:Benzamides; D016376:Oligonucleotides, Antisense; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C509041:TGFB2 protein, human; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2; D000068877:Imatinib Mesylate